Serum Institute of India is a manufacturer of immunobiological drugs including vaccines in the city of Pune, India.
Serum Institute of India is ranked as India’s No. 1 biotechnology company, manufacturing highly specialized life saving biologicals like vaccines using cutting edge genetic and cell based technologies, antisera and other medical specialties.
Serum Institute of India Pvt. Ltd. is now the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines
Serum Institute of India to manufacture ~1 billion doses of NVX-CoV2373 in 2021
Serum Institute of India has established the most modern laboratories with high-tech machinery and computerized equipment for the production and testing of its life saving biologicals. Serum Institute’s commitment to global health is exemplified by significant investments in its infrastructure. The production facilities are continuously upgraded to ensure compliance with cGMP regulations and have been accredited by the World Health Organization, Geneva.
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19.
Serum Institute of India has crossed many milestones in technological advancement by installing robotic arm for virus handling, cell factory and cell cube for growing cells, facilities for the manufacture of polysaccharide and recombinant vaccines and for monoclonal antibodies.
Sophisticated tunnel systems, high speed vial washing, filling, stoppering and sealing machines are capable of working at a speed of 500 containers per minute and have been installed with filling accuracy to the third digit of decimal point to ensure accuracy and consistency.
Serum Institute of India has the latest technology screeners to inspect its products for any minute particulate matter undetectable to the normal human eye. Configured with high resolution CCD cameras and electronic controlled panel, the inspection is done fully automatically, thus reducing the margins of human errors.
With the licensure of additional facilities, Serum Institute of India has the flexibility to produce vaccines in more than one plant, thus facilitating production of large number of doses in the shortest time frame. This enables the Institute to improve the response time to cater to any international emergency or outbreak.
Serum Institute’s entire facility is built to comply with the highest international standards. With a view to enter new markets with an expanded product portfolio, Serum Institute has achieved another milestone, that of getting US FDA compliance for its new plant manufacturing pharmaceutical Injections.